Similar articles

• Some aspects of the critical evaluation of peptic ulcer therapy in patients.

  Mózsik G, Bertelli A, Deak G, Nagy L, Patty I, Simon L, Tárnok F, Jávor T. Mózsik G, et al. Int J Clin Pharmacol Res. 1985;5(6):447-55. Int J Clin Pharmacol Res. 1985. PMID: 4093220
• [Multicenter controlled clinical studies on the effectiveness of pirenzepin in the treatment of peptic ulcer].

  Gibiński K, Nowak A, Hasik J, Klincewicz H, Marlicz K, Gabryelewicz A, Kosidło S. Gibiński K, et al. Pol Tyg Lek. 1982 Nov 8;37(43):1277-80. Pol Tyg Lek. 1982. PMID: 6761671 Clinical Trial. Polish. No abstract available.
• Present and future treatment of peptic ulcer and potential role of DE-NOL.

  [No authors listed] [No authors listed] Scand J Gastroenterol Suppl. 1982;80:49-57. Scand J Gastroenterol Suppl. 1982. PMID: 6761852 Clinical Trial. No abstract available.
• [Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states].

  Bulgakov SA. Bulgakov SA. Klin Med (Mosk). 1995;73(5):11-6. Klin Med (Mosk). 1995. PMID: 8815266 Review. Russian. No abstract available.
• [Antacids and peptic ulcer].

  Vianello F, Di Mario F, Naccarato R. Vianello F, et al. G Clin Med. 1990 Feb;71(2):123-6, 129-31. G Clin Med. 1990. PMID: 2189774 Review. Italian. No abstract available.